Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.

This study found that supplementing myo-inositol with microlipodispersed magnesium significantly improved acne and hirsutism in women with PCOS by reducing BMI, testosterone, and DHEAS levels, also enhancing quality of life without side effects, over 6 months.

This review covers the diagnosis, complications, and management strategies for Polycystic Ovarian Disease, reporting no new clinical results and highlighting the potential of personalized medicine.

In this study, the authors reported that while deoxycholic acid effectively reduces submental fat, it can cause adverse effects such as edema, numbness, and skin necrosis, making knowledge of possible complications essential for clinicians.

In this study, low doses of cyproterone acetate with ethinylestradiol were as effective as low-dose flutamide in reducing acne severity in hyperandrogenic women, while finasteride was less effective.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

This study suggests that stimulating olfactory receptors in human hair follicles with Sandalore® increases antimicrobial activity by upregulating dermcidin production, potentially offering a novel approach for treating hair follicle diseases with bacterial issues.

This review discusses the pathophysiology of polycystic ovary syndrome and its non-pharmacological and pharmacological treatment options, but reports no new clinical results.

This study found that a once-daily capsule of minoxidil and spironolactone may safely reduce hair loss severity in women with female pattern hair loss.

This review discusses the role of hormones in acne vulgaris and highlights the need for further research on their mechanisms of action; it reports no new clinical results.

This study evaluates the use of 5 mg/day finasteride for treating patterned hair loss in normo-androgenetic postmenopausal women, although results are not included in the abstract.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

The authors of this study concluded that higher calcium levels in hair may indicate early metabolic changes leading to osteopenia or osteoporosis in menopausal women, even before detectable by standard DEXA imaging.

This study found that a combination of the Tri-energy factor 5.5% booster and photodynamic therapy significantly improved hair density and reduced single follicular units in patients with androgenetic alopecia, compared to minoxidil or booster alone, supporting the inclusion of photodynamic therapy in comprehensive treatment.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.

This article summarizes lessons and tips from the Dermatology Nurses’ Association’s annual conference, sharing insights on various dermatology topics but does not present new research results.

In this study, ozenoxacin was found to inhibit sebum production in insulin- and 5α-DHT-differentiated hamster sebocytes in a dose-dependent manner, suggesting potential benefits in acne management by combining antimicrobial activity against C. acnes with reduced sebum production.

This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.

This study found that six-month supplementation with fish-derived collagen peptides, calcium, and vitamin D3 improved skin hydration and elasticity and reduced hair loss in menopausal women, with collagen playing a dominant role in enhancing skin elasticity.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.

This chapter reviews secondary uses for various drugs, noting that some have regulatory approval, indicating verified safety and efficacy, while others lack approval despite strong evidence.

In this study, women with polycystic ovary syndrome showed significantly higher levels of DHEA, IL-6, and TNF-α compared to healthy controls, indicating a possible link between these biomarkers and PCOS.

This narrative review discusses adverse effects associated with 5-ARI treatments for male-pattern baldness and benign prostate hyperplasia, including sexual health, neurological, endocrine, metabolic, and cardiovascular impacts, and emphasizes careful prescription assessment.

This article reviews existing strategies for managing polycystic ovarian disease and highlights the role of lifestyle changes, natural remedies, and conventional treatments, reporting no new clinical results.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.